Trial Profile
Azacitidine Compared to Conventional Chemotherapy in Consolidation of Elderly Patients (65 Years or Older) With AML in First Complete Remission
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Cytarabine; Daunorubicin
- Indications Acute myeloid leukaemia
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 21 Sep 2015 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
- 25 Feb 2013 New trial record